Application Note│Comprehensive Profiling of Approved Anti-CD20 mAbs Using Fc Effector Function Platform

Summary

CD20 is a key target for treating B-cell malignancies, enabling selective B-cell depletion. This study compared Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), revealing distinct profiles of known and previously unreported Fc-effector functions, offering insights into mechanisms of antibody efficacy and safety.

This study uses the advanced SeromYx Fc-effector function platform to profile marketed anti-CD20 mAbs, comparing their biophysical binding and cellular Fc functions by leveraging a well-characterized recombinant human full-length CD20-VLPs from ACROBiosystems, aiming to deepen understanding of their potential mechanisms of action and clinical implications.

Key Findings

• Biophysical binding assays are predictive of Fc-driven cellular functions
• SeromYx’s platform recapitulates known Fc effector functions of marketed anti-CD20 mAbs
• Identification of previously unreported effector functions may guidedevelopment of improved CD20 mAbs

Download The Application Note Here